HC Wainwright Has Negative Estimate for IN8bio Q2 Earnings

IN8bio, Inc. (NASDAQ:INAB) – Research analysts at HC Wainwright decreased their Q2 2025 earnings per share (EPS) estimates for IN8bio in a research report issued on Thursday, May 8th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.05) per share for the quarter, down from their prior forecast of ($0.04). HC Wainwright has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for IN8bio’s current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for IN8bio’s FY2025 earnings at ($0.19) EPS and FY2026 earnings at ($0.19) EPS.

IN8bio Trading Down 6.3%

INAB opened at $0.16 on Monday. IN8bio has a twelve month low of $0.13 and a twelve month high of $1.74. The company has a 50-day simple moving average of $0.19 and a 200 day simple moving average of $0.26. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $14.29 million, a price-to-earnings ratio of -0.21 and a beta of 0.23.

IN8bio (NASDAQ:INAB) last released its earnings results on Thursday, May 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.01).

Hedge Funds Weigh In On IN8bio

Several hedge funds have recently bought and sold shares of INAB. Jane Street Group LLC lifted its holdings in shares of IN8bio by 296.7% during the 4th quarter. Jane Street Group LLC now owns 115,919 shares of the company’s stock worth $30,000 after acquiring an additional 86,696 shares during the period. Geode Capital Management LLC lifted its stake in IN8bio by 56.5% during the fourth quarter. Geode Capital Management LLC now owns 515,193 shares of the company’s stock worth $133,000 after purchasing an additional 185,919 shares during the last quarter. Sigma Planning Corp boosted its holdings in shares of IN8bio by 22.3% in the 4th quarter. Sigma Planning Corp now owns 1,041,380 shares of the company’s stock valued at $268,000 after purchasing an additional 190,100 shares in the last quarter. Alyeska Investment Group L.P. raised its holdings in shares of IN8bio by 1,064.5% during the 4th quarter. Alyeska Investment Group L.P. now owns 5,063,291 shares of the company’s stock worth $1,302,000 after buying an additional 4,628,482 shares in the last quarter. Finally, Franklin Resources Inc. bought a new stake in shares of IN8bio during the 4th quarter worth $1,465,000. 92.05% of the stock is owned by institutional investors.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.